Inhibikase Therapeutics (IKT) Net Cash Flow (QoQ) (2020 - 2026)
Inhibikase Therapeutics (IKT) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -188.80% |
| Dec 31, 2025 | 355.75% |
| Sep 30, 2025 | -1,017.70% |
| Jun 30, 2025 | -74.62% |
| Mar 31, 2025 | -69.50% |
| Dec 31, 2024 | 2,657.58% |
| Sep 30, 2024 | -396.41% |
| Jun 30, 2024 | 110.76% |
| Mar 31, 2024 | -19.59% |
| Dec 31, 2023 | -143.96% |
| Sep 30, 2023 | 731.55% |
| Jun 30, 2023 | 36.52% |
| Mar 31, 2023 | -329.76% |
| Dec 31, 2022 | 105.32% |
| Sep 30, 2022 | -500.84% |
| Jun 30, 2022 | -6.28% |
| Mar 31, 2022 | -1.05% |
| Dec 31, 2021 | -105.76% |
| Sep 30, 2021 | -105.35% |
| Jun 30, 2021 | 957.00% |